Leukemia and Lymphoma

A recent study found that higher spleen volume before undergoing allogeneic hematopoietic stem cell transplantation (HSCT) was associated with worse overall survival and higher nonrelapse mortality incidence in patients with acute myeloid leukemia (AML).

Wojciech Jurczak, MD, PhD, head of the Department of Oncology at Maria Sklodowska-Curie National Research Institute of Oncology, discusses the changing therapy landscape for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Following positive phase 2 results from the ROSEWOOD study, BeiGene is seeking FDA approval of zanubrutinib plus obinutuzumab for select patients with relapsed/refractory (R/R) follicular lymphoma.

Fabian Lang, MD, of Goethe University Hospital in Frankfurt, Germany, discussed the importance of good communication between health care providers and patients with chronic myeloid leukemia (CML).

In a disease such as chronic myeloid leukemia (CML), shared treatment decision-making between providers and patients is key, said Fabian Lang, MD, of Goethe University Hospital in Frankfurt, Germany.

Measurable residual disease (MRD) can predict disease progression in patients who have acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL) and chronic myeloid leukemia (CML).

Presentations on the first day of the 2023 American Society of Clinical Oncology Annual Meeting covered data on a split dose CAR T-cell therapy and a CAR T therapy manufactured with TKI.

The therapy is still not widely used among older patients who have diffuse large B-cell lymphoma (DLBCL).

The study was conducted to provide insight into real-world Bruton tyrosine kinase (BTK) inhibitor treatment patterns in mantle cell lymphoma, as current data are limited.

A panel of experts at the American Society of Clinical Oncology Annual Meeting presented the latest research and equity considerations for chimeric antigen receptor (CAR) T-cell therapy in hematological cancers.

Glofitamab is the first bispecific antibody with a fixed-duration treatment for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Tycel Phillips, MD, hematologist-oncologist at City of Hope in Duarte, California, discusses the need for novel treatments for patients with diffuse large B-cell lymphoma (DLBCL).

With the number of treatment options in hematology and oncology rapidly expanding, so too are the strategies for determining and ensuring cost-effectiveness, according to session speakers at the European Hematology Association (EHA) 2023 Congress.

A friendly debate held at the European Hematology Association 2023 Congress focused on the potential for real-world data to improve the generalizability of clinical trial results but also acknowledged the limitations and current challenges with these data.

In some cases, individuals of Puerto Rican descent face lower risk than other Hispanic groups in the United States.

Two studies, one of zanubrutinib alone and one that combined the therapy with tislelizumab, showed promising results in a subset of patients.

A recent study suggests that monitoring anxiety and distress levels during watch-and-wait disease management time frames may improve the patient experience.

Florida Cancer Specialists recently released a case study that outlined its role in the evolution of a first-line therapy for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) that recently received FDA approval.

China’s National Medical Products Administration has approved 2 supplemental new drug applications of zanubrutinib for use in untreated adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma and Waldenström macroglobulinemia.

Daiichi Sankyo announced that the new deadline for review of the application is July 24, 2023.

The FDA has approved polatuzumab vedotin-piiq plus rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for certain patients with treatment-naive diffuse large B-cell lymphoma.

Researchers collected physical function measures and blood samples from 24 patients enrolled in a 16-week trial of at-home aerobic and/or resistance exercise.

An April 1 session at the 2023 National Comprehensive Cancer Network (NCCN) on updates in CLL/SLL featured results on the ALPINE study, which led to the January 2023 approval of zanubrutinib in the frontline setting.

Colocating cancer diagnostic services in in community health centers serving historically marginalized populations resulted in reduced time to a diagnosis.

Although minimal residual disease (MRD) has emerged as a valuable prognostic marker across several hematological malignancies, its use in chronic lymphocytic leukemia (CLL) is mostly limited to clinical trials.